Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Knutson

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Neuropharmacology|July 18, 2018
The α6 subunit-containing GABA<sub>A</sub> receptor: A novel drug target for inhibition of trigeminal activationPi-Chuan Fan, Tzu-Hsuan Lai, Chia Chun Hor, et al.
Molecular Pharmaceutics|February 19, 2020
The Effects of pH on the Structure and Bioavailability of Imidazobenzodiazepine-3-Carboxylate MIDD0301M S Rashid Roni, Guanguan Li, Brandon N Mikulsky, et al.
European Journal of Pain (London, England)|January 12, 2019
Trigeminal neuropathic pain development and maintenance in rats are suppressed by a positive modulator of α6 GABA<sub>A</sub> receptorsDina Vasović, Branka Divović, Marco Treven, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 28, 2022
Targeting α6GABA<sub>A</sub> receptors as a novel therapy for schizophrenia: A proof-of-concept preclinical study using various animal modelsMing Tatt Lee, Akihiro Mouri, Hisayoshi Kubota, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 6, 2023
Freeze-dried nanocrystal dispersion of novel deuterated pyrazoloquinolinone ligand (DK-I-56-1): Process parameters and lyoprotectant selection through the stability studyJelena R Mitrović, Maja Bjelošević Žiberna, Aleksandar Vukadinović, et al.
Current Drug Metabolism|December 3, 2021
Identification and Quantification of MIDD0301 MetabolitesM S Rashid Roni, Nicolas M Zahn, Brandon N Mikulsky, et al.
ACS Pharmacology & Translational Science|December 21, 2020
Nebulized MIDD0301 Reduces Airway Hyperresponsiveness in Moderate and Severe Murine Asthma ModelsNicolas M Zahn, Brandon N Mikulsky, M S Rashid Roni, et al.
Pharmaceutics|August 28, 2021
Overcoming the Low Oral Bioavailability of Deuterated Pyrazoloquinolinone Ligand DK-I-60-3 by Nanonization: A Knowledge-Based ApproachJelena R Mitrović, Branka Divović-Matović, Daniel E Knutson, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 23, 2020
Nanocrystal dispersion of DK-I-56-1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: Formulation approach toward improved in vivo performanceJelena R Mitrović, Branka Divović, Daniel E Knutson, et al.
Pharmacology, Biochemistry, and Behavior|January 18, 2022
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disordersJeffrey M Witkin, Arnold Lippa, Jodi L Smith, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Neuropharmacology|July 18, 2018
The α6 subunit-containing GABA<sub>A</sub> receptor: A novel drug target for inhibition of trigeminal activationPi-Chuan Fan, Tzu-Hsuan Lai, Chia Chun Hor, et al.
Molecular Pharmaceutics|February 19, 2020
The Effects of pH on the Structure and Bioavailability of Imidazobenzodiazepine-3-Carboxylate MIDD0301M S Rashid Roni, Guanguan Li, Brandon N Mikulsky, et al.
European Journal of Pain (London, England)|January 12, 2019
Trigeminal neuropathic pain development and maintenance in rats are suppressed by a positive modulator of α6 GABA<sub>A</sub> receptorsDina Vasović, Branka Divović, Marco Treven, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 28, 2022
Targeting α6GABA<sub>A</sub> receptors as a novel therapy for schizophrenia: A proof-of-concept preclinical study using various animal modelsMing Tatt Lee, Akihiro Mouri, Hisayoshi Kubota, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|August 6, 2023
Freeze-dried nanocrystal dispersion of novel deuterated pyrazoloquinolinone ligand (DK-I-56-1): Process parameters and lyoprotectant selection through the stability studyJelena R Mitrović, Maja Bjelošević Žiberna, Aleksandar Vukadinović, et al.
Current Drug Metabolism|December 3, 2021
Identification and Quantification of MIDD0301 MetabolitesM S Rashid Roni, Nicolas M Zahn, Brandon N Mikulsky, et al.
ACS Pharmacology & Translational Science|December 21, 2020
Nebulized MIDD0301 Reduces Airway Hyperresponsiveness in Moderate and Severe Murine Asthma ModelsNicolas M Zahn, Brandon N Mikulsky, M S Rashid Roni, et al.
Pharmaceutics|August 28, 2021
Overcoming the Low Oral Bioavailability of Deuterated Pyrazoloquinolinone Ligand DK-I-60-3 by Nanonization: A Knowledge-Based ApproachJelena R Mitrović, Branka Divović-Matović, Daniel E Knutson, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 23, 2020
Nanocrystal dispersion of DK-I-56-1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: Formulation approach toward improved in vivo performanceJelena R Mitrović, Branka Divović, Daniel E Knutson, et al.
Pharmacology, Biochemistry, and Behavior|January 18, 2022
The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disordersJeffrey M Witkin, Arnold Lippa, Jodi L Smith, et al.
Pageof 3